Interleukin-6 in blood and bronchoalveolar lavage fluid of hospitalized children with community-acquired pneumonia.
C-reactive protein
bronchoalveolar lavage fluid
children
community-acquired pneumonia
disease severity
erythrocyte sedimentation rate
interleukin-6
pathogen detected
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
04
2022
accepted:
16
08
2022
entrez:
26
9
2022
pubmed:
27
9
2022
medline:
27
9
2022
Statut:
epublish
Résumé
Host biomarkers and cytokines help in the prediction of disease severity in adults with community-acquired pneumonia (CAP). Accurate assessment of pathogens and disease severity is essential to clinical decision-making. There are few validated prognostic tools in blood and bronchoalveolar lavage for children with CAP to assist with proper decision and management. We performed a retrospective study of 118 children under 18 years of age, hospitalized for CAP with bronchoalveolar lavage management within the first 2 days. The primary outcome was disease severity: mild (with no complications), moderate (with mild to moderate complications), and severe (with severe complications). Comparison and performance analysis of biomarkers and cytokines in the blood or bronchoalveolar lavage fluid (BALF) across different severity categories/different pathogens were performed. Analysis of 118 CAP cases revealed significant differences in the BALF levels of IL-6 ( BALF IL-6 and blood CRP levels, and ESR may have the ability for discriminating disease severity in hospitalized children with CAP, whereas WBC count and ANC have limited ability. No biomarkers or cytokines seemed to have the ability to predict the pathogen category, while BALF IL-6, blood ANC, and ESR may assist in the diagnosis of single MP, bacteria, and virus infections, respectively.
Sections du résumé
Background
UNASSIGNED
Host biomarkers and cytokines help in the prediction of disease severity in adults with community-acquired pneumonia (CAP). Accurate assessment of pathogens and disease severity is essential to clinical decision-making. There are few validated prognostic tools in blood and bronchoalveolar lavage for children with CAP to assist with proper decision and management.
Methods
UNASSIGNED
We performed a retrospective study of 118 children under 18 years of age, hospitalized for CAP with bronchoalveolar lavage management within the first 2 days. The primary outcome was disease severity: mild (with no complications), moderate (with mild to moderate complications), and severe (with severe complications). Comparison and performance analysis of biomarkers and cytokines in the blood or bronchoalveolar lavage fluid (BALF) across different severity categories/different pathogens were performed.
Results
UNASSIGNED
Analysis of 118 CAP cases revealed significant differences in the BALF levels of IL-6 (
Conclusion
UNASSIGNED
BALF IL-6 and blood CRP levels, and ESR may have the ability for discriminating disease severity in hospitalized children with CAP, whereas WBC count and ANC have limited ability. No biomarkers or cytokines seemed to have the ability to predict the pathogen category, while BALF IL-6, blood ANC, and ESR may assist in the diagnosis of single MP, bacteria, and virus infections, respectively.
Identifiants
pubmed: 36160800
doi: 10.3389/fped.2022.922143
pmc: PMC9494568
doi:
Types de publication
Journal Article
Langues
eng
Pagination
922143Informations de copyright
Copyright © 2022 Zhang, Zheng, Ning, Liu, Li and Ju.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Infect Dis. 2015 May;15(5):535-43
pubmed: 25801458
Clin Microbiol Infect. 2009 Nov;15(11):1026-32
pubmed: 19548923
Am J Med. 2008 Mar;121(3):219-25
pubmed: 18328306
Clin Infect Dis. 2014 Apr;58(7):918-24
pubmed: 24532543
Nat Rev Rheumatol. 2020 Jun;16(6):335-345
pubmed: 32327746
Mycoses. 2017 Dec;60(12):818-825
pubmed: 28877383
Eur Respir J. 2012 May;39(5):1144-55
pubmed: 22075489
Zhongguo Dang Dai Er Ke Za Zhi. 2017 Nov;19(11):1174-1179
pubmed: 29132465
J Immunol. 1973 Oct;111(4):1194-205
pubmed: 4728681
Scand J Infect Dis. 2004;36(3):198-203
pubmed: 15119365
J Exp Med. 1994 Oct 1;180(4):1243-50
pubmed: 7931061
Pediatrics. 2016 Oct;138(4):
pubmed: 27688362
Arch Pediatr Adolesc Med. 2012 Dec;166(12):1155-64
pubmed: 23027409
N Engl J Med. 2015 Feb 26;372(9):835-45
pubmed: 25714161
Pediatrics. 2020 Jun;145(6):
pubmed: 32404432
Vaccine. 2015 Aug 26;33(36):4623-9
pubmed: 26116251
Crit Care Med. 2005 Jan;33(1):1-6; discussion 230-2
pubmed: 15644641
BMC Infect Dis. 2007 Mar 02;7:10
pubmed: 17335562
Emerg Microbes Infect. 2020 Dec;9(1):1123-1130
pubmed: 32475230
Clin Infect Dis. 2011 Oct;53(7):e25-76
pubmed: 21880587
Respir Res. 2009 Jul 12;10:65
pubmed: 19594893
PLoS One. 2020 Jun 4;15(6):e0232610
pubmed: 32497137
Clin Chem Lab Med. 2015 Mar;53(4):559-66
pubmed: 25014522
Intensive Care Med. 2002 Jul;28(7):834-41
pubmed: 12122519
Cytokine. 2020 Jan;125:154794
pubmed: 31400641
Ann Thorac Med. 2014 Jul;9(3):162-7
pubmed: 24987476
Nature. 1986 Nov 6-12;324(6092):73-6
pubmed: 3491322
Front Immunol. 2019 Aug 02;10:1798
pubmed: 31428097
Pediatr Pulmonol. 2020 Nov;55(11):3088-3095
pubmed: 32770770
Indian J Pediatr. 2017 Sep;84(9):681-684
pubmed: 28534218